International Journal of COPD (Dec 2021)
Chinese Medical Injections for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Network Meta-analysis
Abstract
Haiyin Hu,1,* Zhaochen Ji,1,* Xiaoyu Qiang,1 Shigang Liu,2 Xiaodi Sheng,1 Zhe Chen,1 Fanqi Liu,3 Hui Wang,1 Junhua Zhang1 1Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China; 2Department of Respiratory Diseases, Guang’anmen Hospital, Beijing, People’s Republic of China; 3Department of Cardiovascular Disease, The Second Affiliated Hospital of Tianjin University of Chinese Medicine, Tianjin, People’s Republic of China*These authors contributed equally to this workCorrespondence: Hui Wang, Junhua Zhang Email [email protected]; [email protected]: The World Health Organization has indicated that chronic obstructive pulmonary disease (COPD) may become the third leading cause of death by 2030. Acute exacerbation of COPD (AECOPD) is an important process in clinical treatment. Recent studies have shown that Chinese medical injections (CMI) are effective against AECOPD, but the effective difference among different CMIs remains unclear. The aim of this network meta-analysis (NMA) is to compare the therapeutic effect of various CMIs.Methods: We conducted an overall, systematic literature search in the China National Knowledge Infrastructure, Wanfang, VIP, SinoMed, PubMed, Embase, Cochrane Library, and Web of Science databases to retrieve randomized controlled trials (RCTs) of CMIs for AECOPD published up to January 2021. The Cochrane risk of bias tool was used to assess the risk of bias. Stata 13.1 and WinBUGS 14.3 were used for data analyses.Results: In total, 103 RCTs involving 8767 participants and 23 CMIs were included. The results indicated that among all treatments conventional Western medical therapy (WM) plus Dengzhanxixin injection (DZXX) led to the best improvement in the clinical efficacy and the ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) (FEV1/FVC), with surface under the cumulative ranking curve (SUCRA)=80.47% and 98.55%, respectively. Moreover, Shenmai injection (SM) plus WM and Reduning injection (RDN) plus WM led to the best improvement in the FEV1 (SUCRA=80.18%) and the ratio of forced expiratory volume in one second to the predicted value (FEV1%, SUCRA=87.28%). Shengmai injection (SGM) plus WM led to the most considerable shortening in the length of hospital stay (SUCRA=94.70%). Cluster analysis revealed that WM+DZXX had the most favorable response for clinical efficacy and FEV1, as well as clinical efficacy and FEV1/FVC, WM+RDN had the most favorable response for clinical efficacy and FEV1%, WM+SGM had the most favorable response for clinical efficacy and length of hospital stay.Conclusion: WM+DZXX, WM+RDN, and WM+SGM were noted to be the optimum treatment regimens for improving in clinical efficacy, FEV1, FEV1/FVC, FEV1% and reducing the hospital stay length of AECOPD patients. Considering the limitations this NMA may have, the current results warrant further verification via additional high-quality studies.Keywords: traditional Chinese medicine, TCM, Chinese medical injection, CMI, acute exacerbation of chronic obstructive pulmonary disease, AECOPD, COPD, network meta-analysis, NMA
